Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was ...

The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.

Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations ...

Genetic medicine firm Sarepta Therapeutics announced the tragic death of a young man with Duchenne muscular dystrophy (DMD) ...

A patient has died while receiving Elevidys, a gene therapy for Duchenne muscular dystrophy, marking the first kno ...

The tragic death of the 16-year-old boy came as a result of acute liver failure, which is a known side effect of Elevidys and ...

The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...

We recently published a list of 10 Firms Heavily Hit by Market Pessimism. In this article, we are going to take a look at ...

Shares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after ...

A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ...

Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...

Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that ...